Anti‑Tetanus Immunization Guidelines

Primary Immunization Series for Adults

Adults with unknown or incomplete tetanus vaccination history should receive a 3‑dose primary series: first dose Tdap (preferred), second dose Td or Tdap ≥ 4 weeks after the first, and third dose Td or Tdap 6–12 months after the second 1, 2, 3.
Tdap may substitute for any single dose within the primary series when needed 4, 3.
Persons with uncertain vaccination history should be treated as unvaccinated and follow the primary series protocol 5.
Adults who completed the childhood DTaP series require only a single Tdap dose if they have never previously received Tdap 1, 2.

Decennial Booster Recommendations

After the initial Tdap, routine booster doses every 10 years may be administered with either Td or Tdap 6, 4.
The 2019 ACIP update permits this flexibility, replacing the earlier requirement for Td‑only boosters 6, 7.
Boosters administered at 10‑year intervals maintain protection against tetanus and diphtheria 1, 2.
Tdap should not be delayed when indicated and may be given regardless of the interval since the last tetanus‑containing vaccine 7, 4.
Intervals as short as 2 years from the last Td dose are acceptable when Tdap is specifically indicated 3.

Pregnancy Immunization

Every pregnant woman should receive a Tdap dose during each pregnancy, irrespective of prior Tdap history 1, 2.
The optimal timing is at 27–36 weeks’ gestation to maximize passive antibody transfer to the newborn 1, 2.
Both licensed Tdap products (Adacel and Boostrix) may be used in pregnancy with the same intervals and restrictions as for non‑pregnant persons 8, 6.
Pregnant women who have never been vaccinated should start a 3‑dose primary series during pregnancy: first dose as soon as feasible, second dose ≥ 4 weeks later, third dose 6 months after the second 9.
Td is preferred for the doses given during pregnancy, although one dose may be substituted with Tdap 9.
Receiving at least two properly spaced doses during pregnancy provides minimal risk of neonatal tetanus 5.

Wound Management

Decision Algorithm Based on Vaccination History

Patients with ≥ 3 documented tetanus toxoid doses
- Clean, minor wounds: give tetanus vaccine only if ≥ 10 years have elapsed since the last dose; no TIG required 5.
- Tetanus‑prone wounds: give tetanus vaccine only if ≥ 5 years have elapsed since the last dose; no TIG required 5.
- No prophylaxis is needed if the last dose was < 5 years ago for any wound type 5.
Patients with < 3 documented doses or unknown history
- Clean, minor wounds: give tetanus vaccine only 5.
- Tetanus‑prone wounds: give tetanus vaccine plus TIG 250 units IM 5.
Tetanus‑prone wound characteristics include contamination with dirt, feces, soil, or saliva; puncture or avulsion injuries; and injuries from missiles, crushing, burns, or frostbite 5.

Vaccine Selection for Wound Management

Persons ≥ 11 years: Tdap is preferred if they have never received Tdap or if Tdap history is unknown 5.
Pregnant women: always use Tdap regardless of prior Tdap status 4, 5.
Non‑pregnant persons with documented prior Tdap: use Td when tetanus vaccination is indicated 5; if Td is unavailable, Tdap may substitute 5.
Children < 7 years: use DTaP 5.
The 2019 update allows either Td or Tdap for wound management after the initial Tdap dose 6, 4.

Administration Technique When Both Products Are Needed

When both TIG and tetanus vaccine are indicated, administer them using separate syringes at different anatomic sites 5, 9.

Special Populations

Immunocompromised (HIV‑infected or severely immunodeficient) patients with contaminated wounds should receive TIG regardless of their tetanus immunization history 5.
Patients with a prior Arthus reaction: defer tetanus vaccination until > 10 years after the most recent dose, even for tetanus‑prone wounds; consider a monovalent tetanus toxoid if the reaction was to diphtheria toxoid only 5, 9.
Adults ≥ 65 years: a single Tdap dose is recommended for those who have not previously received Tdap 7, 4; either Tdap product is acceptable, although only Boostrix is FDA‑approved for this age group 7, 4.

Documentation, Serology, and History

Never assume vaccination status; treat individuals with unknown history as unvaccinated 5.
Serologic testing for tetanus and diphtheria antitoxin levels (> 0.01 IU/mL) may be considered when documentation is unavailable but vaccination is likely 5.

Product Information and Availability

Two Tdap products are licensed in the United States: Boostrix (approved for persons ≥ 10 years) and Adacel (approved for ages 10–64 years) 7, 4.
Adacel is FDA‑approved for a second dose if ≥ 8 years have passed since the first Tdap dose 8, 6.
Boostrix may be used for any dose in individuals who have previously received Tdap 8, 6.

Maternal Immunization Timing

Administering Tdap at 27–36 weeks’ gestation optimizes passive antibody transfer to the newborn, enhancing early protection 1, 2.

Tetanus Prophylaxis in Wound Management

Decision Algorithm Based on Vaccination History and Wound Type

The CDC (MMWR) recommends that tetanus prophylaxis decisions depend on two factors: (1) the patient’s tetanus vaccination history (complete primary series of ≥3 doses vs. unknown or <3 doses) and (2) wound classification (clean/minor vs. tetanus‑prone). Timing of the last tetanus‑containing vaccine determines whether a booster is needed. 10
Clean, minor wounds are defined as simple, uncontaminated injuries. 10
Tetanus‑prone wounds include those contaminated with dirt, feces, soil, saliva; puncture wounds; avulsions; missile, crushing, burn, or frostbite injuries. 10, 11

Patients with Unknown or < 3 Doses of Tetanus Toxoid

For clean, minor wounds, give a tetanus toxoid‑containing vaccine only (no TIG required). 10, 11
For tetanus‑prone wounds, give both a tetanus toxoid‑containing vaccine and tetanus immune globulin (TIG) 250 U IM. 10, 11

Patients with ≥ 3 Doses (Completed Primary Series)

For clean, minor wounds, administer a tetanus toxoid‑containing vaccine only if ≥ 10 years have elapsed since the last dose. 10, 11
For tetanus‑prone wounds, administer a tetanus toxoid‑containing vaccine only if ≥ 5 years have elapsed since the last dose (no TIG needed). 10, 11
Patients vaccinated < 5 years ago require no additional tetanus prophylaxis for any wound. 10, 11

Vaccine Selection for Wound Management

For individuals ≥ 11 years needing a tetanus toxoid‑containing vaccine, Tdap is preferred if the patient has never received Tdap or the Tdap history is unknown. 10, 11
Pregnant women should receive Tdap regardless of prior Tdap status. 10, 11
Non‑pregnant persons with documented prior Tdap should receive Td when tetanus vaccination is indicated. 10, 11
If Td is unavailable, Tdap may be used as a substitute. 10, 11
Children < 7 years should receive DTaP. 10, 11
The 2019 ACIP update permits either Td or Tdap for decennial boosters and for wound management after the initial Tdap dose, providing greater flexibility. 12

Administration When Both TIG and Vaccine Are Indicated

Administer TIG and the tetanus toxoid‑containing vaccine using separate syringes at different anatomical sites. 10, 11, 13
The recommended TIG dose is 250 units IM for all age groups. 14
Do not delay wound care while attempting to obtain vaccination history. 14

Special Populations

Immunocompromised Patients

Persons with HIV infection or severe immunodeficiency who sustain contaminated wounds should receive TIG regardless of their prior tetanus immunization status. 10, 11, 15

Patients with Prior Arthus Reaction

Individuals who have experienced an Arthus reaction to tetanus toxoid should avoid further tetanus vaccination until > 10 years have passed since the most recent dose, irrespective of wound severity. 16, 17, 15
For these patients, the TIG decision follows the standard rule: give TIG if the patient has documented < 3 tetanus toxoid doses. 16, 17

Primary Immunization for Unvaccinated Adults

Adults with no prior tetanus vaccination should receive a 3‑dose series:
Tdap may substitute for any dose within this primary series. 18, 19
Persons with unknown or uncertain vaccination history should be treated as unvaccinated. 10, 11, 13

Mass‑Casualty and Resource‑Limited Settings

When TIG supply is limited, reserve TIG for patients least likely to have adequate prior vaccination—specifically, individuals > 60 years old and immigrants from regions outside North America or Europe. 14
If vaccination history cannot be confirmed in a mass‑casualty scenario and the patient has a tetanus‑prone wound, administer a tetanus toxoid vaccine if TIG is unavailable. 14
The majority of wounds in disaster settings are tetanus‑prone due to environmental contamination. 14

Routine Booster Recommendations

A routine tetanus‑diphtheria booster is recommended every 10 years after completion of the primary series. 10, 20
Either Td or Tdap is acceptable for the decennial booster per the 2019 ACIP update. 20, 12

All statements are derived from CDC (MMWR) recommendations and ACIP updates, with citation identifiers provided for each fact.